Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00315263 · ClinicalTrials.gov registry record
Genomics, Single Nucleotide Polymorphisms (SNPs), and Clinical Neonatology
A clinical trial, sponsored by Children's Mercy Hospital Kansas City.
- Completed
- Registry status
- 63
- Enrollment target
NCT00315263: Completed study, sponsored by Children's Mercy Hospital Kansas City.
NCT00315263 is a clinical trial that has completed, run by Children's Mercy Hospital Kansas City. The registered enrollment target is 63 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00315263 has completed, sponsored by Children's Mercy Hospital Kansas City.
- COMPLETED
- Registry status
- 63 participants
- Enrollment target
Study Summary
This research seeks to establish a neonatal DNA Tissue Bank to find out if differences in small segments of DNA predispose babies to Chronic Lung Disease (CLD), Periventricular Brain Injury (PVI), Necrotizing Enterocolitis (NEC), or Hypoxic Respiratory Failure (HRF).
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 63 participants |
| Start Date | 2006-04 |
| Est. Completion | 2011-07 |
What the finished NCT00315263 record still lists
NCT00315263 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 63 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT00315263 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00315263 about?
NCT00315263 is a clinical study titled "Genomics, Single Nucleotide Polymorphisms (SNPs), and Clinical Neonatology". This research seeks to establish a neonatal DNA Tissue Bank to find out if differences in small segments of DNA predispose babies to Chronic Lung Disease (CLD), Periventricular Brain Injury (PVI), Necrotizing Enterocolitis (NEC), or Hypoxic Respiratory Failure (HRF).
What is the current status of trial NCT00315263?
This trial is currently completed. The enrollment target is 63 participants. The study started on 2006-04. Estimated completion is 2011-07.
Who is sponsoring clinical trial NCT00315263?
This trial is sponsored by Children's Mercy Hospital Kansas City, which has 184 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03383575 · 63 participants · Phase 2
Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome
- NCT04870944 · 63 participants · Phase 1
CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma
- NCT05031897 · 63 participants · Phase 2
Two Step Haplo With Radiation Conditioning
- NCT05312671 · 63 participants · Phase 2
Atezolizumab Plus Etoposide and Platinum in Small Cell Bladder Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia